clinical pipeline

Clinical Pipeline

CLINICAL PIPELINE

Indication View
Molecule View
Indication
Line
Regimena,b
Phase 1
Phase 1b
Randomized Phase 2
Indication:

NSCLC

Regimen:

dom + zim ± etruma

Phase 1
Phase 1b
Randomized Phase 2
Regimen:

etruma + zim + carbo/pem

Phase 1
Phase 1b
Randomized Phase 2
Indication:

mCRPC

Regimen:

etruma + zim + enza

Phase 1
Phase 1b
Randomized Phase 2
Regimen:

etruma + zim + doce

Phase 1
Phase 1b
Randomized Phase 2
Regimen:

etruma + zim

Phase 1
Phase 1b
Randomized Phase 2
Regimen:

etruma + AB680 ± zim

Phase 1
Phase 1b
Randomized Phase 2
Indication:

CRC

Regimen:

etruma + rego + atezo

Phase 1
Phase 1b
Randomized Phase 2
Regimen:

etruma + FOLFOX

Phase 1
Phase 1b
Randomized Phase 2
Indication:

PDAC

Regimen:

etruma + atezo + gem/nab-pac

Phase 1
Phase 1b
Randomized Phase 2
Regimen:

AB680 + zim + gem/nab-pac

Phase 1
Phase 1b
Randomized Phase 2
Indication:

TNBC

Regimen:

etruma + PLD

Phase 1
Phase 1b
Randomized Phase 2
Regimen:

etruma + IPI-549 + PLD||

Phase 1
Phase 1b
Randomized Phase 2
Indication:

Pan-Tumor

Regimen:

zim monotherapy§

Phase 1
Phase 1b
Randomized Phase 2
Moleculea,b
Indication
Line
Regimen
Phase 1
Phase 1b
Phase 2
Molecule:

Etrumadenant
(ETRUMA)

Dual A2a/A2b Adenosine Receptor Antagonist Small Molecule

Indication:

CRPC

Regimen:

etruma + zim

Phase 1
Phase 1b
Phase 2
Indication:

CRPC

Regimen:

etruma + zim ± (AB680 or enza or doce)

Phase 1
Phase 1b
Phase 2
Indication:

CRC

Regimen:

etruma + rego + atezo

Phase 1
Phase 1b
Phase 2
Indication:

CRC

Regimen:

etruma + FOLFOX

Phase 1
Phase 1b
Phase 2
Indication:

NSCLC

Regimen:

dom + zim + carbo/pem

Phase 1
Phase 1b
Phase 2
Indication:

NSCLC

Regimen:

dom + zim ± etruma

Phase 1
Phase 1b
Phase 2
Indication:

PDAC

Regimen:

etruma + atezo + gem/nab-pac

Phase 1
Phase 1b
Phase 2
Indication:

TNBC

Regimen:

etruma + PLD

Phase 1
Phase 1b
Phase 2
Indication:

TNBC

Regimen:

etruma + IPI-549 + PLD||

Phase 1
Phase 1b
Phase 2
Molecule:

AB680

CD73 Inhibitor Small Molecule

Indication:

PDAC

Regimen:

AB680 + zim + gem/nab-pac

Phase 1
Phase 1b
Phase 2
Molecule:

Domvanalimab
(DOM)

Anti-TIGIT Antibody

Indication:

NSCLC

Regimen:

dom + zim ± etruma

Phase 1
Phase 1b
Phase 2
Indication:

Multiple Cancer Types

Regimen:

dom + zim

Phase 1
Phase 1b
Phase 2
Molecule:

Zim­ber­eli­mab
(ZIM)

Anti-PD-1 Antibody

Indication:

Biomarker Selected (tumor-type agnostic)

Regimen:

All lines§

Phase 1
Phase 1b
Phase 2


Etrumadenant: Dual A2aR/A2bR Antagonist Small Molecule
AB680: CD73 Inhibitor Small Molecule
Domvanalimab: TIGIT mAb
Zimberelimab: PD-1 mAb

These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.

ABBREVIATIONS:
Dom: domvanalimab; Etruma: etrumadenant; Zim: zimberelimab; Doce: docetaxel; Enza: enzalutamide; Atezo: atezolizumab; Rego: regorafenib; Carbo/Pem: carboplatin/pemetrexed; Bev: bevacizumab; Gem/Nab-pac: gemcitabine/nab-paclitaxel; PLD: pegylated liposomal doxorubicin; SOC: standard of care

CRC=colorectal cancer; CRPC=castrate-resistant prostate cancer; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma; TNBC=triple-negative breast cancer;

PARTNERSHIPS & COLLABORATIONS:

gilead logo (a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The parties will co-develop Gilead-optioned programs globally, and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.

taiho logo (b) In September 2017, Arcus and Taiho announced an option and license agreement. Taiho has an option to Arcus’s programs arising during the 5-year term for Japan and certain other Asian territories (excluding China).

Clinical collaboration with Genentech, Member of the Roche Group.
||Clinical collaboration with Infinity Pharmaceuticals.
§Clinical collaboration with Strata Oncology.


Etrumadenant: Dual A2aR/A2bR Antagonist Small Molecule
AB680: CD73 Inhibitor Small Molecule
Domvanalimab: TIGIT mAb
Zimberelimab: PD-1 mAb

These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.

ABBREVIATIONS:
Dom: domvanalimab; Etruma: etrumadenant; Zim: zimberelimab; Doce: docetaxel; Enza: enzalutamide; Atezo: atezolizumab; Rego: regorafenib; Carbo/Pem: carboplatin/pemetrexed; Bev: bevacizumab; Gem/Nab-pac: gemcitabine/nab-paclitaxel; PLD: pegylated liposomal doxorubicin; SOC: standard of care

CRC=colorectal cancer; CRPC=castrate-resistant prostate cancer; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma; TNBC=triple-negative breast cancer;

PARTNERSHIPS & COLLABORATIONS:

gilead logo (a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The parties will co-develop Gilead-optioned programs globally, and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.

taiho logo (b) In September 2017, Arcus and Taiho announced an option and license agreement. Taiho has an option to Arcus’s programs arising during the 5-year term for Japan and certain other Asian territories (excluding China).

Clinical collaboration with Genentech, Member of the Roche Group.
||Clinical collaboration with Infinity Pharmaceuticals.
§Clinical collaboration with Strata Oncology.